Celavet Product Development
Celavet’s product development is geared towards enabling injured horses to regain their fullest potential as competitors, performers, workers, and companions. In 2012, the global equine healthcare market was recorded at US$26.6 billion (Transparency Market Research).
Offering a fast path to market, Celavet’s stem cell therapies are in development with applications for tendon and ligament injuries. Our products for the treatment and prevention of orthopedic injuries will have value in the veterinary marketplace.
| Disease | Candidate | Preclinical | Clinical |
|---|---|---|---|
| Tendinitis (e.g., tendon injuries, bowed tendons, ect.) | Equine | ||
| Musculoskeletal injuries | Equine | ||
| Osteoarthritus | Canine | ||
| Ligaments tendons | Canine | ||
| Burns | Canine | ||
| Kidney Desease | Feline |
Products in Celavet Pipeline
Celavet has 3 sets of cultured stem cell lines:
- Equine cells (OK100) for the treatment of musculoskeletal injuries
- Canine cells (OK200) for the treatment of musculoskeletal injuries, wounds and burns
- Feline cells (OK300)
The Center for Veterinary Medicine (CVM) approved Celavet’s equine donor screening protocol and cell product characterization (2017).
